Pharsight

Drugs that contain Omadacycline Tosylate

1. Nuzyra patents expiration

NUZYRA's oppositions filed in EPO
Can you believe NUZYRA received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7326696 PARATEK PHARMS INC Amino-methyl substituted tetracycline compounds
Sep, 2023

(6 months ago)

US7553828 PARATEK PHARMS INC 9-aminomethyl substituted minocycline compounds
Jun, 2024

(a month from now)

US8383610 PARATEK PHARMS INC Salts and polymorphs of 9-(2,2-dimethylpropyl-aminomethyl) minocycline
Sep, 2030

(6 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9365500 PARATEK PHARMS INC 9-aminomethyl substituted minocycline compounds
Jun, 2021

(2 years ago)

US9265740 PARATEK PHARMS INC Minocycline compounds and methods of use thereof
Mar, 2029

(4 years from now)

US9724358 PARATEK PHARMS INC Minocycline compounds and methods of use thereof
Mar, 2029

(4 years from now)

US10124014 PARATEK PHARMS INC Minocycline compounds and methods of use thereof
Mar, 2029

(4 years from now)

US9314475 PARATEK PHARMS INC Oral and injectable formulations of tetracycline compounds
Mar, 2031

(6 years from now)

US10111890 PARATEK PHARMS INC 9-aminomethyl minocycline compounds and uses thereof
Aug, 2037

(13 years from now)

US10383884 PARATEK PHARMS INC 9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (CABP)
Oct, 2037

(13 years from now)

US10835542 PARATEK PHARMS INC 9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (CABP)
Oct, 2037

(13 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Oct 02, 2023
Generating Antibiotic Incentives Now(GAIN) Oct 02, 2028

NCE-1 date: 03 October, 2027

Market Authorisation Date: 02 October, 2018

Treatment: Treatment of bacterial skin and skin structure infections; Treatment of bacterial skin and skin structure infection; Treatment of subjects having bacterial skin or skin structure infection; Treatment ...

Dosage: POWDER;INTRAVENOUS; TABLET;ORAL

More Information on Dosage

NUZYRA family patents

Family Patents